Rigosertib Free Base | CAS# 592542-59-1 (free base) | Plk1 inhibitor

Rigosertib Free Base
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414575

CAS#: 592542-59-1 (free base)

Description: Rigosertib Free Base is a Plk1 inhibitor with antineoplastic activity.

Chemical Structure

Rigosertib Free Base

CAS# 592542-59-1 (free base)

Instruction

Theoretical Analysis

MedKoo Cat#: 414575
Name: Rigosertib Free Base
CAS#: 592542-59-1 (free base)
Chemical Formula: C21H25NO8S
Exact Mass: 451.13
Molecular Weight: 451.490
Elemental Analysis: C, 55.87; H, 5.58; N, 3.10; O, 28.35; S, 7.10

Price and Availability

Size	Price	Availability
25mg	USD 450	2 Weeks
50mg	USD 750	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 592542-59-1 (free base) 1225497-78-8 (sodium) 592542-60-4 (sodium)

Synonym: Rigosertib Free Base; ON01910; ON-01910; ON 01910

IUPAC/Chemical Name: Glycine, N-(2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) methyl)phenyl)-

InChi Key: OWBFCJROIKNMGD-BQYQJAHWSA-N

InChi Code: InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+

SMILES Code: O=C(O)CNC1=CC(CS(=O)(/C=C/C2=C(OC)C=C(OC)C=C2OC)=O)=CC=C1OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 451.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, Rai A, Cho MY, Stern JJ, Prota AE, Kampmann M, Akhmanova A, Steinmetz MO, Tanenbaum ME, Weissman JS. Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent. Mol Cell. 2020 Jul 2;79(1):191-198.e3. doi: 10.1016/j.molcel.2020.06.008. PMID: 32619469; PMCID: PMC7332992.

2: Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, Rai A, Cho MY, Stern JJ, Prota AE, Kampmann M, Akhmanova A, Steinmetz MO, Tanenbaum ME, Weissman JS. Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent. Mol Cell. 2017 Oct 5;68(1):210-223.e6. doi: 10.1016/j.molcel.2017.09.012. PMID: 28985505; PMCID: PMC5640507.

3: Baker SJ, Cosenza SC, Athuluri-Divakar S, Reddy MVR, Vasquez-Del Carpio R, Jain R, Aggarwal AK, Reddy EP. A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent. Mol Cell. 2020 Jul 2;79(1):180-190.e4. doi: 10.1016/j.molcel.2020.05.024. PMID: 32619468.

4: Kowalczyk JT, Wan X, Hernandez ER, Luo R, Lyons GC, Wilson KM, Gallardo DC, Isanogle KA, Robinson CM, Mendoza A, Heske CM, Chen JQ, Luo X, Kelly AE, Difilippantinio S, Robey RW, Thomas CJ, Sackett DL, Morrison DK, Randazzo PA, Jenkins LMM, Yohe ME. Rigosertib Induces Mitotic Arrest and Apoptosis in RAS- Mutated Rhabdomyosarcoma and Neuroblastoma. Mol Cancer Ther. 2021 Feb;20(2):307-319. doi: 10.1158/1535-7163.MCT-20-0525. Epub 2020 Nov 6. PMID: 33158997; PMCID: PMC7867632.

5: Balaian E, Weidner H, Wobus M, Baschant U, Jacobi A, Mies A, Bornhäuser M, Guck J, Hofbauer LC, Rauner M, Platzbecker U. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes. Ann Hematol. 2019 Sep;98(9):2063-2072. doi: 10.1007/s00277-019-03756-1. Epub 2019 Jul 16. PMID: 31312928.

6: Günther JK, Nikolajevic A, Ebner S, Troppmair J, Khalid S. Rigosertib- Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation. Biology (Basel). 2020 May 15;9(5):99. doi: 10.3390/biology9050099. PMID: 32429320; PMCID: PMC7284707.

7: Navada SC, Silverman LR. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2016 Aug;16(8):805-10. doi: 10.1080/14737140.2016.1209413. Epub 2016 Jul 15. PMID: 27400247.

8: Atanasova VS, Pourreyron C, Farshchian M, Lawler M, Brown CA 4th, Watt SA, Wright S, Warkala M, Guttmann-Gruber C, Hofbauer JP, Fuentes I, Prisco M, Rashidghamat E, Has C, Salas-Alanis JC, Palisson F, Hovnanian A, McGrath JA, Mellerio JE, Bauer JW, South AP. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma. Clin Cancer Res. 2019 Jun 1;25(11):3384-3391. doi: 10.1158/1078-0432.CCR-18-2661. Epub 2019 Mar 7. PMID: 30846478; PMCID: PMC8185613.

9: Rahmani F, Asgharzadeh F, Avan A, Barneh F, Parizadeh MR, Ferns GA, Ryzhikov M, Ahmadian MR, Giovannetti E, Jafari M, Khazaei M, Hassanian SM. Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-κB signaling pathways. Life Sci. 2020 May 15;249:117470. doi: 10.1016/j.lfs.2020.117470. Epub 2020 Mar 2. PMID: 32135184.

10: Navada SC, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Demakos EP, Zbyszewski PS, Maniar M, Woodman RC, Fruchtman SM, Silverman LR. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leuk Res. 2020 Jul;94:106369. doi: 10.1016/j.leukres.2020.106369. Epub 2020 May 12. PMID: 32442785.

Your view history

Rigosertib Free Base featured